IMPA2 blocks cervical cancer cell apoptosis and induces PTX resistance through p53-mediated AIFM2 regulation

Kexin Xie,Lei Liu,Min Wang,Xianping Li,Bingqi Wang,Sheng Yin,Wanxin Chen,Xiaolin Zhu,Yinrui Lin

DOI: https://doi.org/10.3724/abbs.2023069

IF: 3.7

2023-03-01

Acta Biochimica et Biophysica Sinica

Abstract:Cervical cancer continues to be a concern, and the prognosis of locally advanced cervical cancer remains poor. <i>IMPA2</i> was previously identified as a potential oncogene and regulator of tumor apoptosis. In this study, we aim to further elucidate the underlying mechanisms of <i>IMPA2</i> gene in the regulation of cervical cancer apoptosis. First, we identify <i>AIFM2</i> as an upregulated gene in <i>IMPA2</i>-silenced cervical cancer cells, and inhibition of <i>AIFM2</i> reverses <i>IMPA2</i> knockdown-induced apoptosis. Further study reveals that <i>AIFM2</i> regulates cell apoptosis in a mitochondrial-dependent manner with a redistribution of mitochondrial membrane potential and intracellular Ca ²⁺ levels. However, the analysis of the STRING database and our experimental results show that <i>AIFM2</i> has little effect on cervical cancer progression and survival. Further mechanistic study demonstrates that <i>IMPA2</i> and <i>AIFM2</i> silencing inhibits apoptosis by activating p53. Meanwhile, the knockdown of <i>IMPA2</i> enhances the chemosensitivity of cervical cancer cells by strengthening paclitaxel-induced apoptosis. Based on the above results, the IMPA2/AIFM2/p53 pathway may be a new molecular mechanism for paclitaxel treatment of cervical cancer and an effective strategy to enhance the sensitivity of cervical cancer cells to paclitaxel. Our findings display a novel function of <i>IMPA2</i> in regulating cell apoptosis and paclitaxel resistance mediated by a disturbance of <i>AIFM2</i> and <i>p53</i> expression, potentially making it a novel therapeutic target for cervical cancer treatment.

biochemistry & molecular biology,biophysics